The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment

Ghaderi, A. and Banafshe, H.R. and Mirhosseini, N. and Motmaen, M. and Mehrzad, F. and Bahmani, F. and Aghadavod, E. and Mansournia, M.A. and Reiter, R.J. and Karimi, M.-A. and Asemi, Z. (2019) The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment. Addiction Biology, 24 (4). pp. 754-764.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

This investigation was designed to determine the effect of melatonin supplementation on mental health parameters, metabolic and genetic profiles in patients under methadone maintenance treatment (MMT). This randomized, double-blind, placebo-controlled, clinical trial was conducted among 54 patients under MMT. Participants were randomly allocated to receive either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 26) or placebo (n = 28) once a day, 1 hour before bedtime for 12 weeks. Melatonin supplementation significantly decreased Pittsburgh Sleep Quality Index (β �4.08; 95 percent CI, �5.51, �2.65; P < 0.001), Beck Depression Inventory index (β �5.46; 95 CI, �8.92, �2.00; P = 0.003) and Beck Anxiety Inventory index (β �3.87; 95 CI, �5.96, �1.77; P = 0.001) and significantly increased International Index of Erectile Functions (β 5.59; 95 CI, 1.76, 9.42; P = 0.005) compared with the placebo. Subjects who received melatonin supplements had significantly lower serum insulin levels (β �2.53; 95 CI, �4.48, �0.59; P = 0.01), homeostasis model of assessment-insulin resistance (β �0.56; 95 CI, �1.03, �0.09; P = 0.01) and higher quantitative insulin sensitivity check index (β 0.01; 95 CI, 0.004, 0.02; P = 0.009) and HDL-cholesterol levels (β 3.71; 95 CI, 1.77, 5.64; P = 0.002) compared to placebo. Additionally, melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (β �0.15; 95 CI, �0.27, �0.02; P = 0.02), malondialdehyde (β �0.31; 95 CI, �0.57, �0.05; P = 0.02) and protein carbonyl (β �0.06; 95 CI, �0.09, �0.04; P < 0.001). This trial indicated that taking melatonin supplements for 12 weeks by patients under MMT had beneficial effects on their mental health metabolic profiles. © 2018 Society for the Study of Addiction

Item Type: Article
Additional Information: cited By 9
Uncontrolled Keywords: benzodiazepine; C reactive protein; carbonyl derivative; high density lipoprotein cholesterol; insulin; malonaldehyde; melatonin; methadone; placebo; protein derivative; serotonin uptake inhibitor, adult; aged; Article; Beck Anxiety Inventory; Beck Depression Inventory; bedtime dosage; C reactive protein blood level; cholesterol blood level; controlled study; daytime somnolence; dizziness; double blind procedure; drug capsule; drug effect; genetic parameters; headache; homeostasis model assessment; human; human cell; insulin blood level; insulin sensitivity; International Index of Erectile Function; major clinical study; male; mental disease; metabolic disorder; methadone treatment; Pittsburgh Sleep Quality Index; priority journal; protein blood level; quantitative analysis; randomized controlled trial; supplementation; treatment duration
Subjects: Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Department of Biochemistry
Depositing User: ART . editor
Date Deposited: 31 Dec 2019 11:43
Last Modified: 31 Dec 2019 11:43
URI: http://eprints.kaums.ac.ir/id/eprint/4516

Actions (login required)

View Item View Item